Abstract
Leukemias are well suited to proteomic profiling by RPPA due to the ready accessibility of blasts from the blood or marrow. In this review, we review methodological and procedural issues that affect the quality of RPPA data. We recommend contact printers that minimize sample quantities and evaporation and maximize sample per slide. The impact of sample selection and handling is reviewed as well. Protein is best prepared fresh on the date of acquisition as cryopreservation changes protein expression levels in some diseases. Rapid processing is also required to avoid changes in phosphorylation over time. Sample source, blood vs. marrow does not seem to affect results as long as leukemic blast enrichment procedures are utilized. The choice of the correct “normal” control is important for comparing diseased to “normal” expression. Various means of normalizing the data are discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kornblau SM, Tibes R, Qiu Y et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113:154–164.
Kornblau SM, Qiu YH, Chen W et al. Proteomic Profiling of 150 Proteins in 511 Acute Myelogenous Leukemia (AML) Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications [abstract]. Blood 2008;112:281–282.
Accordi B, Espina V, Lissandron V et al. Phosphoproteomic profiling of pediatric B-ALL patients with MLL rearrangements [abstract]. Journal of Clinical Oncology 2008;26:539S.
Kornblau SM, Qui YH, Tibes R, Lu Y, Mills G. Time Course Proteomic Profiling of Signal Transduction and Apoptosis Pathways in AML Survivor Cells Using Reverse Phase Protein Lysate Microarray (RPPA) Reveals Differential Effect of Time, Dose and Agent(s). [abstract]. Blood 2005;106:355a.
Tibes R, Qiu YH, Lu Y et al. Reverse Phase Protein Array (RPPA): Validation of a Novel Proteomic Technology and Utility for Analysis of Primary Leukemia Specimens and Hemato-poetic Stem Cells (HSC). Mol Cancer Ther 2006;5:2512–2521.
Baker AF, Dragovich T, Ihle NT et al. Stability of phosphoprotein as a biological marker of tumor signaling. Clin.Cancer Res. 2005;11:4338–4340.
Ferrer I, Santpere G, Arzberger T et al. Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks:a BrainNet Europe Study. J.Neuropathol.Exp.Neurol. 2007;66:35–46.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–111.
Neeley ES, Kornblau SM, Coombes KR, Baggerly KA. Variable slope normalization of reverse phase protein arrays. Bioinformatics. 2009;25:1384–1389.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Kornblau, S.M., Coombes, K.R. (2011). Use of Reverse Phase Protein Microarrays to Study Protein Expression in Leukemia: Technical and Methodological Lessons Learned. In: Korf, U. (eds) Protein Microarrays. Methods in Molecular Biology, vol 785. Humana Press. https://doi.org/10.1007/978-1-61779-286-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-61779-286-1_10
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-285-4
Online ISBN: 978-1-61779-286-1
eBook Packages: Springer Protocols